In vitro dissolution similarity factor (f2) and in vivo bioequivalence criteria, how and when do they match? Using a BCS class II drug as a simulation example

European Journal of Pharmaceutical Sciences

Volumn 66, Issue , 2015, Pages 163-172

  Xie, Feifan ^a   Ji, Shan ^a   Cheng, Zeneng ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Bioequivalence; Dissolution; First order; Numerical convolution; Similarity factor; Simulation

Indexed keywords

FELODIPINE;

AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; COMPUTER SIMULATION; DISSOLUTION SIMILARITY FACTOR; DRUG SOLUBILITY; IN VITRO STUDY; IN VIVO STUDY; MAXIMUM PLASMA CONCENTRATION; PLASMA CONCENTRATION-TIME CURVE; REFERENCE VALUE; TABLET; TIME TO MAXIMUM PLASMA CONCENTRATION; BIOLOGICAL MODEL; CHEMICAL MODEL; DRUG RELEASE; MEDICINAL CHEMISTRY; THERAPEUTIC EQUIVALENCE;

AREA UNDER CURVE; CHEMISTRY, PHARMACEUTICAL; COMPUTER SIMULATION; DRUG LIBERATION; MODELS, BIOLOGICAL; MODELS, CHEMICAL; THERAPEUTIC EQUIVALENCY;

EID: 84910679899     PISSN: 09280987     EISSN: 18790720     Source Type: Journal    
DOI: 10.1016/j.ejps.2014.10.002     Document Type: Article

References (28)

1. E. Basalious, W. El-Sebaie, and O. El-Gazayerly Application of pharmaceutical QbD for enhancement of the solubility and dissolution of a Class II BCS drug using polymeric surfactants and crystallization inhibitors: development of controlled-release tablets AAPS PharmSciTech 12 2011 799 810
2. S.-C. Chow, and J.-P. Liu Design and Analysis of Bioavailability and Bioequivalence Studies 3rd ed. 2000 CRC Press
3. J.L. Cohen, B.B. Hubert, L.J. Leeson, C.T. Rhodes, J.R. Robinson, T.J. Roseman, and E. Shefter The development of USP dissolution and drug release standards Pharm. Res. 7 1990 983 987
4. P. Costa An alternative method to the evaluation of similarity factor in dissolution testing Int. J. Pharm. 220 2001 77 83
5. P. Costa, and L.J. Sousa Modeling and comparison of dissolution profiles Eur. J. Pharm. Sci. 13 2001 123 133
6. A. Dokoumetzidis, and P. Macheras A century of dissolution research: from Noyes and Whitney to the biopharmaceutics classification system Int. J. Pharm. 321 2006 1 11
7. A. Dokoumetzidis, V. Papadopoulou, and P. Macheras Analysis of dissolution data using modified versions of Noyes-Whitney equation and the Weibull function Pharm. Res. 23 2006 256 261
8. J.B. Dressman, and J. Krämer Pharmaceutical Dissolution Testing 2005 Taylor & Francis Boca Raton
9. J.Z. Duan, K. Riviere, and P. Marroum In vivo bioequivalence and in vitro similarity factor (f2) for dissolution profile comparisons of extended release formulations: how and when do they match? Pharm. Res. 28 2011 1144 1156
10. P.H. Dunselman, and B. Edgar Felodipine clinical pharmacokinetics Clin. Pharmacokinet. 21 1991 418 430
11. J. Emami In vitro - in vivo correlation: from theory to applications J. Pharm. Pharm. Sci. 9 2006 169 189
12. FDA, 1995. Guidance for Industry, Immediate Release Solid Oral Dosage Forms. Scale-up and Postapproval Changes: Chemistry, Manufacturing, and Controls.
13. FDA, 1997. Guidance for Industry: SUPAC-MR: Modified Release Solid Oral Dosage Forms; Scale-Up and Post-Approval Changes: Chemistry, Manufacturing and Controls. Vitro Dissolution Testing, and In Vivo Bioequivalence Documentation.
14. FDA, 2000. Guidance for Industry: Waiver of in vivo Bioavailability and Bioequivalence Studies for Immediate-release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System. Food and Drug Administration, Rockville, MD.
15. FDA, 2001. Guidance for Industry: Statistical Approaches to Establishing Bioequivalence. Center for Drug Evaluation and Research (CDER), Rockville, MD.
16. FDA, 2003. Guidance for Industry: Bioavailability and Bioequivalence Studies for Orally Administered Drug Products - General Considerations. Food and Drug Administration, Washington, DC.
17. Z. Gao In vitro dissolution testing with flow-through method: a technical note AAPS PharmSciTech 10 2009 1401 1405
18. E. Gupta, D. Barends, E. Yamashita, K. Lentz, A. Harmsze, V. Shah, J. Dressman, and R. Lipper Review of global regulations concerning biowaivers for immediate release solid oral dosage forms Eur. J. Pharm. Sci. 29 2006 315 324
19. C.L. Hsiao, Y.C. Wu, and K.Y. Hsu Pharmacokinetics of felodipine extended-release tablets in healthy Taiwanese subjects: a retrospective review Arzneimittelforschung 61 2011 444 451
20. N.B. Modi, A. Lam, E. Lindemulder, B. Wang, and S.K. Gupta Application of in vitro-in vivo correlations (IVIVC) in setting formulation release specifications Biopharm. Drug Dispos. 21 2000 321 326
21. W.J. Moore, and H.H. Flanner Mathematical comparison of dissolution profiles Pharm. Technol. 20 1996 64 74
22. S.A. Qureshi In Vitro-In Vivo Correlation (IVIVC) and determining drug concentrations in blood from dissolution testing - a simple and practical approach Open Drug Delivery J. 4 2010 38 47
23. R.C. Rossi, C.L. Dias, L. Bajerski, A.M. Bergold, and P.E. Froehlich Development and validation of discriminating method of dissolution for fosamprenavir tablets based on in vivo data J. Pharm. Biomed. Anal. 54 2011 439 444
24. V.P. Shah, K.K. Midha, S. Dighe, I.J. McGilveray, J.P. Skelly, A. Yacobi, T. Layloff, C.T. Viswanathan, C.E. Cook, and R.D. McDowall Analytical methods validation: bioavailability, bioequivalence and pharmacokinetic studies. Conference report Eur. J. Drug Metab. Pharmacokinet. 16 1991 249 255
25. Shargel, L., Andrew, B., Wu-Pong, S., 2012. Applied biopharmaceutics & pharmacokinetics. 6th ed. Biopharmaceutic Considerations in Drug Product Design and in Vitro Drug Product Performance. Appleton & Lange Reviews/McGraw-Hill, Medical Pub. Division (Chapter 14).
26. G. Singhvi, A. Shah, N. Yadav, and R.N. Saha Prediction of in vivo plasma concentration-time profile from in vitro release data of designed formulations of milnacipran using numerical convolution method Drug Dev. Ind. Pharm. 2013 1 4
27. A.D. Thomas O'Haraa A review of methods used to compare dissolution profile data Pharm. Sci. Technol. Today 1 1998 214 223
28. Y. Zhang, M. Huo, J. Zhou, A. Zou, W. Li, C. Yao, and S. Xie DDSolver: an add-in program for modeling and comparison of drug dissolution profiles AAPS J. 12 2010 263 271